Lipidomics and in Vitro Azole Resistance in Candida albicans

OMICS A Journal of Integrative Biology

Volumn 17, Issue 2, 2013, Pages 84-93

  Singh, Ashutosh ^a   Mahto, Kaushal Kumar ^a   Prasad, Rajendra ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; LIPIDOME; SPHINGOLIPID; STEROL;

ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; COMPARATIVE STUDY; DISCRIMINANT ANALYSIS; HOMEOSTASIS; IN VITRO STUDY; LIPID ANALYSIS; LIPID COMPOSITION; LIPIDOMICS; MOLECULE; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; AZOLES; CANDIDA ALBICANS; DRUG RESISTANCE, FUNGAL; FATTY ACIDS; GLYCEROPHOSPHOLIPIDS; LIPID METABOLISM; PRINCIPAL COMPONENT ANALYSIS; STEROLS;

EID: 84873347035     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2012.0075     Document Type: Article

References (35)

1. Albertson GD, Niimi M, Cannon RD, and Jenkinson HF. (1996). Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother 40, 2835-2841. (Pubitemid 26404354)
2. Bligh EG, and Dyer WJ. (1959). A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37, 911-917.
3. Chen YL, Montedonico AE, Kauffman S, Dunlap JR, Menn FM, and Reynolds TB. (2010). Phosphatidylserine synthase and phosphatidylserine decarboxylase are essential for cell wall integrity and virulence in Candida albicans. Mol Microbiol 75, 1112-1132.
4. Clark TA, and Hajjeh RA. (2002). Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 15, 569-574. (Pubitemid 36026968)
5. Cowen LE, Sanglard D, Calabrese D, Sirjusingh C, Anderson JB, and Kohn LM. (2000). Evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol 182, 1515-1522. (Pubitemid 30121114)
6. Dagley MJ, Gentle IE, Beilharz TH, et al. (2011). Cell wall integrity is linked to mitochondria and phospholipid homeostasis in Candida albicans through the activity of the post-transcriptional regulator Ccr4-Pop2. Mol Microbiol 79, 968-989.
7. Ferreira CR, Saraiva SA, Catharino RR, et al. (2010). Single embryo and oocyte lipid fingerprinting by mass spectrometry. J Lipid Res 51, 1218-1227.
8. Han X, and Gross RW. (1994). Electrospray ionization mass pectroscopic analysis of human erythrocyte plasma membrane phospholipids. Proc Natl Acad Sci USA 91, 10635- 10639. (Pubitemid 24329053)
9. Janmey PA, and Kinnunen PKJ. (2006). Biophysical properties of lipids and dynamic membranes. Trends Cell Biol 16, 538- 546. (Pubitemid 44468385)
10. Klappe K, Dijkhuis AJ, Hummel I, et al. (2010). Extensive sphingolipid depletion does not affect lipid raft integrity or lipid raft localization and efflux function of the ABC transporter MRP1. Biochem J 430, 519-529.
11. Kohli A, Smriti, Mukhopadhyay K, Rattan A, and Prasad R. (2002). In vitro low-level resistance to azoles in Candida albicans is associated with changes in membrane lipid fluidity and asymmetry. Antimicrob Agents Chemother 46, 1046- 1052. (Pubitemid 34260349)
12. Lopez-Ribot JL, McAtee RK, Perea S, Kirkpatrick WR, Rinaldi MG, and Patterson TF. (1999). Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 43, 1621-1630. (Pubitemid 29331238)
13. Marie C, and White TC. (2009). Genetic basis of antifungal drug resistance. Curr Fungal Infect Rep 3, 163-169.
14. Michael AQ, and Kelly SL. (2008). The extraction and analysis of sterols from yeast. Methods Mol Biol 53, 123-131.
15. Morschhauser J. (2002). The genetic basis of fluconazole resistance development in Candida albicans. Biochim Biophys Acta 1587, 240-248. (Pubitemid 34655792)
16. Mukhopadhyay K, Kohli A, and Prasad R. (2002). Drug susceptibilities of yeast cells are affected by membrane lipid composition. Antimicrob Agents Chemother 46, 3695- 3705. (Pubitemid 35403239)
17. Mukhopadhyay K, Prasad T, Saini P, Pucadyil TJ, hattopadhyay A, and Prasad R. (2004). Membrane sphingolipid- ergosterol interactions are important determinants of multidrug resistance in Candida albicans. Antimicrob Agents Chemother 48, 1778-1787. (Pubitemid 38544389)
18. Pasrija R, Panwar SL, and Prasad R. (2008). Multidrug ransporters CaCdr1p and CaMdr1p of Candida albicans display different lipid specificities: Both ergosterol and sphingolipids are essential for targeting of CaCdr1p to membrane rafts. Antimicrob Agents Chemother 52, 694- 704. (Pubitemid 351170846)
19. Pasrija R, Prasad T, and Prasad R. (2005). Membrane raft lipid constituents affect drug susceptibilities of Candida albicans. Biochem Soc Trans 33, 1219-1223. (Pubitemid 41659153)
20. Pfaller MA, and Diekema DJ. (2007). Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 20, 133-163. (Pubitemid 46167771)
21. Prasad R, and Kapoor K. (2005). Multidrug resistance in yeast Candida. Int Rev Cytol 242, 215-248. (Pubitemid 39642964)
22. R ezanka T, and Sigler K. (2009). Odd-numbered very-long-chain fatty acids from the microbial, animal and plant kingdoms. Prog Lipid Res 48, 206-238.
23. Richardson MD. (2005). Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 56, i5-i11.
24. Ringner M. (2008). What is principal component analysis? Nat Biotechnol 26, 303-304. (Pubitemid 351355122)
25. Sanglard D, and White TC. (2005). Chapter 14. Molecular Principles of Antifungal Drug Resistance. In: Molecular Principles of Fungal Pathogenesis, Heitman J, Filler SG, Edwards JE, Mitchell AP, eds. Washington, D.C.: ASM Press. pp 197- 212.
26. Sanglard D, Coste A, and Ferrari S. (2009). Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS Yeast Res 9, 1029-1050.
27. Shevchenko A, and Simons K. (2010). Lipidomics: Coming to grips with lipid diversity. Nat Rev Mol Cell Biol 11, 593-598.
28. Shingu-Vazquez M, and Traven A. (2011). Mitochondria and fungal pathogenesis: Drug tolerance, virulence, and potential for antifungal therapy. Eukaryot Cell 10, 1376- 1383.
29. Singh A, and Prasad R. (2011). Comparative lipidomics of azole sensitive and resistant clinical isolates of Candida albicans reveals unexpected diversity in molecular lipid imprints. PLoS One 29, 6:e19266.
30. Singh A, Prasad T, Kapoor K, et al. (2010). Phospholipidome of Candida: Each species of Candida has distinctive phospholipids molecular species. OMICS 14, 665-677.
31. Singh A, Yadav V, and Prasad R. (2012) Comparative lipidomics in clinical isolates of Candida albicans reveal crosstalk between mitochondria, cell wall integrity and azole resistance. PLoS One, 7(6), e39812.
32. Sharma M, Dhamgaye S, Singh A, Prasad R. (2012). Lipidome analysis reveals antifungal polyphenol curcumin affects membrane lipid homeostasis: Targets D5,6 desaturase (ERG3) of Candida albicans. Front Biosci (Elite Ed) 4, 1195-1209.
33. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, and Grillot R. (2006). Candidaemia in Europe: Epidemiology and resistance. Int J Antimicrob Agents 27, 359-366.
34. White TC, Marr KA, and Bowden RA. (1998). Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11, 382-402. (Pubitemid 28197359)
35. Zhang Y-Q, Gamarra S, Garcia-Effron G, Park S, Perlin DS, and Rao R. (2010). Requirement for ergosterol in V-ATPase function underlies antifungal activity of azole drugs. PLoS Pathog 6, e1000939.